Johnson & Johnson aims to test the company’s experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.
Life sciences giant Johnson & Johnson is growing as the company announced the acquisition of Momenta Pharmaceuticals in a $6.5 billion all-cash deal.
Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.
The U.S. Department of Health and Human Services (HHS) said McKesson Corp. will be the central distributor for future coronavirus vaccines, sending the U.S. drug distributor’s shares up more than 3%.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering.
Novavax Inc. said South Korea’s SK bioscience would manufacture a component of the U.S. drug developer’s experimental coronavirus vaccine in a bid to boost the clinical-stage biotechnology company’s supply.
San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.
Shares of Reata Pharmaceuticals plunged more than 33 percent after the company announced a potential delay in plans to seek approval of omaveloxolone, an investigational treatment of Friedreich’s ataxia (FA).
Arcturus Therapeutics Holdings Inc. said the first group of participants were dosed in an early-stage trial testing the company’s Covid-19 vaccine candidate and that results from the trial were expected in fourth-quarter 2020.
Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
